Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories Inc. (NASDAQ: MLAB) is a prominent global entity dedicated to the development, manufacturing, and marketing of superior process validation, monitoring, and calibration instruments and consumables. The company plays a crucial role across numerous regulated applications in the pharmaceutical, healthcare, and medical device sectors, making it a vital player in ensuring product integrity, enhancing patient and worker safety, and elevating the overall quality of life.
Mesa Laboratories operates through four main divisions, each catering to specific industry needs:
- Sterilization and Disinfection Control: This division focuses on producing and selling biological, cleaning, and chemical indicators, alongside offering testing and laboratory services. Their products are indispensable in medical device and pharmaceutical manufacturing sterilization monitoring, including various sterilization methods like steam, EO, H2O2, and chlorine dioxide.
- Biopharmaceutical Development: Specializing in automated systems for protein analysis and peptide synthesis, this segment supports the critical needs of the biopharmaceutical sector, ensuring rigorous quality control and reliability.
- Calibration Solutions: Mesa's offerings in this division include high-quality data loggers for temperature, humidity, and pressure monitoring, as well as NIST-traceable calibration solutions for various parameters essential for health and safety compliance.
- Clinical Genomics: This division caters to the evolving needs of genomic testing and diagnostics, providing advanced solutions that uphold the highest standards of accuracy and reliability.
Among its notable products, Mesa's Phoenix meter and the 90XL meter stand out. The Phoenix meter is a point-of-use dialysate QC meter, whereas the 90XL meter serves as the industry benchmark for dialysis machine calibration.
Financially, Mesa has recently navigated several strategic moves, including the acquisition of GKE entities, which are projected to add significant revenue. Despite facing challenges like the economic slowdown in China impacting their Clinical Genomics division, Mesa has shown resilience with sequential revenue growth driven by their Calibration Solutions division.
Mesa's commitment to innovation and quality is further highlighted by their ongoing projects and partnerships intended to expand their product lines and market reach. The company is focused on leveraging synergies from acquisitions and refining their business strategy, particularly in their Clinical Genomics division, to adapt to regulatory changes and market demands.
For the latest updates and in-depth information about Mesa Laboratories Inc., visit their official website at www.mesalabs.com.
Mesa Laboratories (NASDAQ:MLAB) reported Q2 FY2025 results with revenues increasing 8.8% to $57,833,000, primarily driven by 11% growth from the GKE acquisition. Operating income surged 5,947% to $3,508,000, while net income increased 379%. The company experienced a 2.8% decline in core organic revenues. Notable division performance included Sterilization and Disinfection Control (38% of revenues) declining 5.2% in core organic growth, while Biopharmaceutical Development showed strong growth of 27.9%. The company reduced its debt by $7,438,000, bringing the Net Leverage Ratio to 3.26.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.
Mesa Labs is a global leader in designing and manufacturing life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. The company's products and services aim to ensure product integrity, increase patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB) reported strong Q1 FY2025 results, with revenues increasing 14.9% to $58,170,000 and core organic revenues growth of 3.0%. Operating income surged 940%, while non-GAAP adjusted operating income excluding unusual items rose 47.0% to $15,341,000 or 26.4% of revenues. The company saw growth across most divisions, with Biopharmaceutical Development leading at 23.5% core organic growth. However, Clinical Genomics faced headwinds in China and North America. Mesa Labs repaid $9.4 million in debt, reducing its Net Leverage Ratio to 3.41. The company remains focused on driving profitability and reducing debt, aiming for a ratio below 3.0x.
Mesa Laboratories (NASDAQ: MLAB) has announced a quarterly dividend of $0.16 per share of common stock. The dividend is scheduled for payment on September 16, 2024, to shareholders who are on record as of August 30, 2024.
Mesa Laboratories specializes in designing and manufacturing life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries. The company's products and services aim to ensure product integrity, enhance patient and worker safety, and improve global quality of life.
Mesa Laboratories (NASDAQ: MLAB) reported its fourth quarter and full fiscal year 2024 results. In 4Q24, revenues rose by 6% compared to 4Q23, reaching $58,904, driven by the acquisition of GKE China. However, core organic revenues fell by 3.5%. The company also registered an operating loss of $271,284, due to a significant non-cash impairment charge. Non-GAAP adjusted operating income surged by 26.3%.
For FY24, revenues decreased by 1.3% to $216,187, with core organic revenues dropping 5.4%. The year saw an operating loss of $272,075. Non-GAAP adjusted operating income grew by 0.7%. Mesa Labs' financial performance was impacted by economic slowdowns and headwinds in the biopharmaceutical and clinical genomics sectors, despite gains in other areas and effective cost control measures.
Mesa Laboratories (NASDAQ: MLAB) announced a delay in issuing its unaudited fourth quarter and full fiscal year 2024 financial results, initially scheduled for today. The delay is due to the finalization of year-end audit calculations and technical accounting for previously announced impairments in its Clinical Genomics and Biopharmaceutical Development divisions, as well as purchase accounting for GKE's acquisition. The Form 10-K filing deadline with the SEC is June 14, 2024. Mesa Laboratories is a global leader in life sciences tools and quality control solutions for regulated pharmaceutical, healthcare, and medical device industries.
Mesa Laboratories (NASDAQ:MLAB) has revised the earnings announcement date for its unaudited fourth quarter and full fiscal year 2024 results to May 31, 2024. The press release, disclosing financial outcomes for the period ending March 31, 2024, will be issued at approximately 8:00 A.M. Eastern time on that day.
Mesa's Form 10-K, detailing these results, will also be filed on May 31. The delay is attributed to finalizing calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill in the Clinical Genomics and Biopharmaceutical Development divisions. The deadline for this filing with the SEC is June 14, 2024.
Mesa Laboratories specializes in life sciences tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, ensuring product integrity and improving quality of life globally.
FAQ
What is the current stock price of Mesa Laboratories (MLAB)?
What is the market cap of Mesa Laboratories (MLAB)?
What does Mesa Laboratories Inc. do?
What are the main divisions of Mesa Laboratories?
What are some notable products from Mesa Laboratories?
How has Mesa Laboratories performed financially recently?
What are Mesa Laboratories' recent strategic moves?
How does Mesa Laboratories ensure product integrity and safety?
What kind of services does the Biopharmaceutical Development division offer?
What impact did the acquisition of GKE have on Mesa Laboratories?
What has been the impact of the economic slowdown on Mesa Laboratories?
Where can I find more information about Mesa Laboratories Inc.?
